AIMS: Chronic kidney disease (CKD) challenges diabetes management and is associated with increased cardiovascular morbidity and mortality. We examined whether clinical outcomes with insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (IDeg-100) are affected by renal function in a prespecified subgroup analysis from the BRIGHT trial. MATERIALS AND METHODS: BRIGHT (NCT02738151) was a multicentre, open-label, randomized, active-controlled, two-arm, parallel-group, 24-week study in insulin-naïve uncontrolled type 2 diabetes (T2D). Participants were randomized 1:1 to evening Gla-300 (n = 466) or IDeg-100 (n = 463) and stratified based on baseline estimated glomerular filtration rate (eGFR) for this analysis. RESULTS: Heterogeneity of treatment effect across renal function subgroups was observed (P = .02), reflecting a greater mean glycated haemoglobin (HbA1c) reduction from baseline to week 24 with Gla-300 versus IDeg-100 in the eGFR <60 mL/min/1.73 m2 subgroup (least squares mean difference: -0.43% [95% confidence interval: -0.74% to -0.12%]), while there were no differences in hypoglycaemia incidence or rates over 24 weeks in that subgroup. HbA1c reductions were similar between treatments in the other eGFR subgroups. However, heterogeneity was observed for annualized rates of anytime (24 hours) or nocturnal (00:00-05:59 hours) confirmed hypoglycaemia (≤70 mg/dL [≤3.9 mmol/L]) over 24 weeks showing less hypoglycaemia with Gla-300 versus IDeg-100 in the ≥90 mL/min/1.73 m2 . CONCLUSIONS: Kidney function seems to affect the glucose-lowering effects of Gla-300 versus IDeg-100 in insulin-naïve T2D. Greater HbA1c reductions with Gla-300 without increase in hypoglycaemia risk, were observed in patients with eGFR <60 mL/min/1.73 m2 .

Dallas Diabetes Research Center at Medical City Dallas Texas

Department of Cardiology University Hospital RWTH Aachen Aachen Germany

Department of Diabetes and Endocrinology Guy's and St Thomas' NHS Trust London UK

Department of Medicine University of Toronto Toronto Ontario Canada

Diabetes Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Ividata Levallois Perret France

Sanofi Paris France

Section of Endocrinology and Metabolism Department of Medicine Perugia University Medical School Perugia Italy

000      

00000naa a2200000 a 4500

001      

bmc21020287

003      

CZ-PrNML

005      

20210830101916.0

007      

ta

008      

210728s2020 xxk f 000 0|eng||

009      

AR

024    7_

$a 10.1111/dom.14043 $2 doi

035    __

$a (PubMed)32243043

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Haluzík, Martin $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

245    10

$a Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial / $c M. Haluzík, A. Cheng, D. Müller-Wieland, J. Westerbacka, Z. Bosnyak, F. Lauand, L. Melas-Melt, J. Karalliedde, J. Rosenstock, GB. Bolli

520    9_

$a AIMS: Chronic kidney disease (CKD) challenges diabetes management and is associated with increased cardiovascular morbidity and mortality. We examined whether clinical outcomes with insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (IDeg-100) are affected by renal function in a prespecified subgroup analysis from the BRIGHT trial. MATERIALS AND METHODS: BRIGHT (NCT02738151) was a multicentre, open-label, randomized, active-controlled, two-arm, parallel-group, 24-week study in insulin-naïve uncontrolled type 2 diabetes (T2D). Participants were randomized 1:1 to evening Gla-300 (n = 466) or IDeg-100 (n = 463) and stratified based on baseline estimated glomerular filtration rate (eGFR) for this analysis. RESULTS: Heterogeneity of treatment effect across renal function subgroups was observed (P = .02), reflecting a greater mean glycated haemoglobin (HbA1c) reduction from baseline to week 24 with Gla-300 versus IDeg-100 in the eGFR <60 mL/min/1.73 m2 subgroup (least squares mean difference: -0.43% [95% confidence interval: -0.74% to -0.12%]), while there were no differences in hypoglycaemia incidence or rates over 24 weeks in that subgroup. HbA1c reductions were similar between treatments in the other eGFR subgroups. However, heterogeneity was observed for annualized rates of anytime (24 hours) or nocturnal (00:00-05:59 hours) confirmed hypoglycaemia (≤70 mg/dL [≤3.9 mmol/L]) over 24 weeks showing less hypoglycaemia with Gla-300 versus IDeg-100 in the ≥90 mL/min/1.73 m2 . CONCLUSIONS: Kidney function seems to affect the glucose-lowering effects of Gla-300 versus IDeg-100 in insulin-naïve T2D. Greater HbA1c reductions with Gla-300 without increase in hypoglycaemia risk, were observed in patients with eGFR <60 mL/min/1.73 m2 .

650    12

$a diabetes mellitus 2. typu $x komplikace $x farmakoterapie $7 D003924

650    _2

$a regulace glykemie $7 D000085002

650    _2

$a lidé $7 D006801

650    _2

$a hypoglykemika $x škodlivé účinky $7 D007004

650    _2

$a inzulin glargin $x škodlivé účinky $7 D000069036

650    _2

$a dlouhodobě působící inzulin $7 D049528

650    _2

$a ledviny $7 D007668

655    _2

$a časopisecké články $7 D016428

655    _2

$a multicentrická studie $7 D016448

655    _2

$a randomizované kontrolované studie $7 D016449

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Cheng, Alice $u Department of Medicine, University of Toronto, Toronto, Ontario, Canada

700    1_

$a Müller-Wieland, Dirk $u Department of Cardiology, University Hospital RWTH Aachen, Aachen, Germany

700    1_

$a Westerbacka, Jukka $u Sanofi, Paris, France

700    1_

$a Bosnyak, Zsolt $u Sanofi, Paris, France

700    1_

$a Lauand, Felipe $u Sanofi, Paris, France

700    1_

$a Melas-Melt, Lydie $u Ividata, Levallois-Perret, France

700    1_

$a Karalliedde, Janaka $u Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Trust, London, UK

700    1_

$a Rosenstock, Julio $u Dallas Diabetes Research Center at Medical City, Dallas, Texas

700    1_

$a Bolli, Geremia B $u Section of Endocrinology and Metabolism, Department of Medicine, Perugia University Medical School, Perugia, Italy

773    0_

$w MED00005425 $t Diabetes, obesity & metabolism $x 1463-1326 $g Roč. 22, č. 8 (2020), s. 1369-1377

856    41

$u https://pubmed.ncbi.nlm.nih.gov/32243043 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20210728 $b ABA008

991    __

$a 20210830101916 $b ABA008

999    __

$a ok $b bmc $g 1690965 $s 1140733

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 22 $c 8 $d 1369-1377 $e 20200428 $i 1463-1326 $m Diabetes, obesity and metabolism $n Diabetes Obes Metab $x MED00005425

GRA    __

$p Sanofi $2 International

LZP    __

$a Pubmed-20210728